DelveInsight’s, “Myocardial Infarction Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 62+ pipeline drugs in the Myocardial Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Myocardial Infarction Treatment Landscape
Request a sample and discover the recent breakthroughs happening in the Myocardial Infarction Pipeline landscape @ Myocardial Infarction Pipeline Outlook
Myocardial Infarction Overview
Myocardial Infarction in which the word infarction means necrosis or death of tissue is commonly known as “Heart attack” and it occurs due to reduced or complete cessation of blood flow to a portion of myocardium resulting in its necrosis due to lack of adequate oxygen supply. The accumulation of plaques, white blood cells, cholesterol, and fat in coronary arteries causes its narrowing and blockage leading to the formation of blood clots which in turn restricts the flow of blood to the heart.
Key Takeaways from the Myocardial Infarction Pipeline Report
Find out more about the Myocardial Infarction Diagnosis and Treatment of patients @ Myocardial Infarction Ongoing Clinical Trials Analysis
Myocardial Infarction Emerging Drugs Profile
Empagliflozin, is an oral, once-daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries. Early use of the SGLT2 inhibitor empagliflozin (Jardiance) after an acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure.
GNR 060, is an investigational drug being developed by GENERIUM Pharmaceuticals.GNR 060, belongs to the class of cardiovascular therapies. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Myocardial Infarction.
FDY-5301 is a patented, formulated, elemental reducing agent containing sodium iodide. It works to catalytically destroy hydrogen peroxide, which is naturally generated as a response to acute ischemia-reperfusion injury and contributes to loss of muscle mass and function. Preclinical studies of FDY-5301 have demonstrated its ability to reduce infarct size, improve cardiac function, and improve skeletal muscle function. Phase I data has demonstrated no signs of toxicity in healthy subjects. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Myocardial Infarction.
Zalunfiban (RUC-4), a next generation GPI, is specifically designed to be administered subcutaneously to inhibit platelet aggregation for a first-point-of-medical contact treatment to improve outcomes for STEMI patients. Inhibiting platelet aggregation can slow or stop blood clot formation leading to coronary artery blockage, and in turn, can stop or prevent a heart attack.
Zalunfiban targets platelet GPIIb/IIIa receptors, the final common pathway in platelet aggregation, to inhibit all platelet activators and can, under some conditions, promote recanalization of occluded arteries. In contrast, other antiplatelet medications, including P2Y12 inhibitors and aspirin, inhibit only one platelet activator and have not been demonstrated to promote recanalization.
Further, due to decreased gastrointestinal absorption, oral P2Y12 inhibitors given before the procedure to open the artery do not act rapidly or reliably enough in STEMI patients during the crucial early minutes of a heart attack and have not demonstrated a clinical benefit to date. It is currently being investigated in Phase III stage of development for the treatment of myocardial infarction.
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa. By working upstream in the contact activation pathway of coagulation, factor XIa inhibitors may prevent pathologic thrombosis, and thus recurrent ischaemic events, but not adversely impact haemostasis, and thus not cause bleeding.
By specifically targeting a protein involved in pathological thrombus formation, but leaving the pathway involved in physiological vessel healing intact, FXIa inhibitors could have the potential to prevent events like stroke and myocardial infarction (MI) without a corresponding increase in bleeding risk. This program is designed to provide further support for the hypothesis that inhibiting FXIa with asundexian can reduce the risk of thrombotic events without increasing the risk of bleeding. Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. Asundexian displays potent anticoagulant activity in vitro in human and rabbit plasma and antithrombotic efficacy in vivo in a rabbit arterial thrombosis model.
OPL-0301, which is being developed by Valo Health, acts by targeting sphingosine-1-phosphate (S1P). It is being developed based on the Opal platform. It is administered orally. Valo believes that as a biased S1P1 agonist, OPL-0301 may avoid the side effects of other S1P1 modulators and therefore unlock therapeutic benefit. It is currently being investigated in the Phase II stage of development for the treatment of post-myocardial infarction.
MEDI6570, which AstraZeneca is developing, inhibits the LOX-1 receptor (anti-LOX-1 mAb). Blockade of the receptor reduced cytokine release via the NFkappaB pathway, inhibited monocyte adhesion, prohibited monocyte differentiation to foam cells and smooth muscle cell apoptosis, and improved endothelial function.
MEDI6570 is suitable for post-MI patients with high residual risk attributed to inflammation via direct inhibition of multi-ligand scavenger receptor involved in oxidized LDL pathogenesis and inflammation. It is currently being investigated in the Phase II stage of development for the treatment of coronary heart disease.
Dutogliptin Tartrate (REC-01), being developed by Recardio, is a potent and selective inhibitor of Dipeptidyl peptidase 4 (DPP4). Dutogliptin is administered via subcutaneous injection.
In May 2022, the company presented the Phase II safety results of the drug at the World Congress on Acute Heart Failure 2022 in Madrid. After reviewing the Phase II trial results, the FDA agreed with the proposed trial design and sample size for the pivotal Phase II trial of dutogliptin in co-administration with filgrastim in early recovery post-myocardial infarction. A comparable agreement was also reached with the EMA.
Recardio is currently planning to initiate its global pivotal Phase III clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
Myocardial Infarction Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Myocardial Infarction. The companies which have their Myocardial Infarction drug candidates in the most advanced stage, i.e. Phase III include, GENERIUM Pharmaceuticals.
Discover more about the list of Myocardial Infarction FDA-approved drugs @ Myocardial Infarction Treatment Landscape
Scope of the Myocardial Infarction Pipeline Report
Dive deep into rich insights for Myocardial Infarction Emerging Therapies and Ongoing Clinical Trials; visit @ Myocardial Infarction Emerging Therapies and Companies
Table of Content
Got Queries? Find out the related information on Myocardial Infarction Mergers and acquisitions, Myocardial Infarction Licensing Activities @ Myocardial Infarction Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/